Navigation Links
BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Date:11/5/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York.

WHEN: Monday November 10th at 12:00pm (Eastern Time)

WHERE: New York Palace Hotel, New York.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, th
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
5. BioMS Medical to present at UBS Global Life Sciences Conference
6. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. BioMS Medical Announces Second Quarter 2008 Results
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. BioMS Medical to present at BMO Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... 2015 The laboratory information management systems ... a number of technological advancements due to factors such ... need to integrate healthcare systems, and increasing government support ... system integration. Key players in the market focus on ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Crystal Diagnostics (CDx) ... that it has received AOAC-PTM Certifications for the six non-O157 ... and O145; collectively referred to as STEC or the “Big-6”) ... colony forming unit (cfu) per 325 g of raw ground ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... to be a fortune teller, but he believes his ... in radiation therapy for some time to come. , ... the Hi-Art System, the company's radiation therapy platform, will ... 250,000 patient fractions, or incremental treatments, have been delivered ...
... It's not too early to gauge the level of ... company formed by Beth Donley and University of ... already is rubbing elbows with interested investors, particularly angels, ... for eventually attracting big dollars from venture capitalists involves ...
... set forth predictions for 2007 is just too hard to resist. ... the next 12 months if you'll send me yours. Mine are ... to chris@guidewiregroup.com before the end of the week). So, ... away , ,Well, not Web 2.0 the development technique to ...
Cached Biology Technology:TomoTherapy sees sustained market advantage 2TomoTherapy sees sustained market advantage 3TomoTherapy sees sustained market advantage 4UW scientist, former WiCell director found stem cell company 2UW scientist, former WiCell director found stem cell company 3Bold prediction: Web 2.0 goes away in 2007 2Bold prediction: Web 2.0 goes away in 2007 3
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2
... discovery of a new molecular signature for a destructive and ... therapeutic target for the hard-to-treat condition. In a study ... atresia, researchers report in the November Journal of Clinical ... the same disease process. Some patients have a second molecular ...
... Results of a study published this week in the journal ... to move to keep up with recent climate change effects in ... The study was supported by the National Science Foundation (NSF), ... and Synthesis at the University of California at Santa Barbara. ...
... MADISON, Wisconsin, November 7, 2011 A 79-year-old ... Northern Research Station are part of a team that ... years. Dan Lindner, a research plant pathologist with ... (CFMR), is one of 13 scientists participating in the ...
Cached Biology News:Possible treatment target found for main cause of severe liver disease in kids 2Possible treatment target found for main cause of severe liver disease in kids 3One if by land, Two if by sea? Climate change 'escape routes' 2Forest Service part of team sequencing 1,000 fungal genomes 2
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Biology Products: